Syneron Medical (ELOS) is an Israel-based company that manufactures and distributes medical aesthetic devices powered by its proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. In the last one year, the shares of Syneron have traded between a low of $7.21 and a high of $11.92. Given Syneron's leadership position in the aesthetic devices market and its recently announced joint venture with Unilever (UL), I feel the stock is meaningfully undervalued at its current level.
Syneron is a global leader in aesthetic devices with 28% worldwide market share. The company's highly innovative ELOS (Electro-Optical Synergy) technology provides the foundation for effective, safe and cost-effective tools that help physicians offer long-lasting...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: